IBD Medication Guide

Ri
Risankizumab-rzaa
Ri

Risankizumab-rzaa

Brand Name(s)

Skyrizi®

Drug Class

Biologics

How taken

intravenous (IV) infusion for first three doses, subcutaneous (under skin) injection after

Used for

In Inflammatory Bowel Disease (IBD), it is used for moderate to severe Crohn's disease

Recommendations for Pregnancy

Insufficient trial data. Monoclonal antibodies may be transported across the placenta

Recommendations for Lactation

Medication indication

This medication is an interleukin-23 antagonist prescribed for the treatment of moderate to severe Crohn's disease in adults.

Indicated for pediatric use

Not indicated for pediatric use

Most common side effects

It may increase risk of infections including upper respiratory or urinary tract infections. Other side effects may include injection site reactions, abdominal pain, headache, and joint pains. Liver injury has been reported (liver enzymes and bilirubin levels should be monitored).

Other

Patients should be evaluated for tuberculosis (TB) prior to starting this medication, and should not be given Skyrizi® if there is active TB. If there is a hypersensitivity reaction or anaphylaxis occurs, discontinue medication and initiate appropriate therapy immediately. Avoid use of live vaccines

Learn more about biologics

Scroll right by clicking & dragging with your cursor or swiping with your finger.